← Back to guidelines
Nutrition27 papers

Polyglandular autoimmune syndrome, type 2

Last edited: 4/15/2026

Overview

Autoimmune Polyglandular Syndrome type 2 (APS-2) is characterized by the association of Addison's disease (primary adrenal insufficiency), autoimmune thyroid disease, and often type 1 diabetes mellitus, along with potential involvement of other endocrine and non-endocrine organs 1.

Diagnosis

  • Key Diagnostic Criteria: Presence of Addison's disease and autoimmune thyroid disease, frequently accompanied by type 1 diabetes mellitus 1.
  • Recommended Tests:
  • - Adrenal function tests (cortisol, ACTH stimulation test) - Thyroid function tests (TSH, free T4) - Autoantibody screening (21-hydroxylase, TPO, GAD)
  • Grading: Diagnosis often made retrospectively with a latency period observed in many patients 1.
  • Management

  • First-Line Treatments:
  • - Glucocorticoids and mineralocorticoids for adrenal insufficiency 1. - Levothyroxine for hypothyroidism 1. - Insulin for type 1 diabetes 1.
  • Adjunctive Treatments:
  • - Vitamin D supplementation due to frequent deficiencies and low bone mineral density 2. - Hydroxycobalamin as an alternative to cyanocobalamin in cases of hypersensitivity reactions 3.

    Special Populations

  • Bone Health: Patients with APS-2 have significantly lower bone mineral density and vitamin D levels, necessitating monitoring and supplementation 2.
  • Hypersensitivity Reactions: Consider alternative forms of vitamin B12 (e.g., hydroxycobalamin) in patients with known hypersensitivity to cyanocobalamin 3.
  • Key Recommendations

  • Regular monitoring of multiple endocrine functions and bone health is essential due to the multisystem involvement in APS-2 (Evidence: Moderate 12).
  • Vitamin D supplementation should be considered to address deficiencies and mitigate bone density issues observed in APS-2 patients (Evidence: Moderate 2).
  • In managing APS-2 patients with suspected B12 deficiency, assess for hypersensitivity to cyanocobalamin and consider hydroxycobalamin as an alternative (Evidence: Weak 3).
  • References

    1 Gatta E, Maltese V, Cimino E, Cavadini M, Anelli V, Di Lodovico E et al.. Evaluation of a large set of patients with Autoimmune Polyglandular Syndrome from a single reference centre in context of different classifications. Journal of endocrinological investigation 2024. link 2 Akkurt Kocaeli A, Erturk E. Bone Mineral Density and Vitamin D Status in Patients with Autoimmune Polyglandular Syndromes: A Single Tertiary Care Center Experience. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2024. link 3 Moloney FJ, Hughes R, O'Shea D, Kirby B. Type I immediate hypersensitivity reaction to cyanocobalamin but not hydroxycobalamin. Clinical and experimental dermatology 2008. link

    Original source

    1. [1]
      Evaluation of a large set of patients with Autoimmune Polyglandular Syndrome from a single reference centre in context of different classifications.Gatta E, Maltese V, Cimino E, Cavadini M, Anelli V, Di Lodovico E et al. Journal of endocrinological investigation (2024)
    2. [2]
      Bone Mineral Density and Vitamin D Status in Patients with Autoimmune Polyglandular Syndromes: A Single Tertiary Care Center Experience.Akkurt Kocaeli A, Erturk E Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme (2024)
    3. [3]
      Type I immediate hypersensitivity reaction to cyanocobalamin but not hydroxycobalamin.Moloney FJ, Hughes R, O'Shea D, Kirby B Clinical and experimental dermatology (2008)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG